NCT06973421

Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer

Preliminary Phase II Clinical Study on the Efficacy and Safety of the Combination of Utidelone Capsules and Fruquintinib Capsules in the Treatment of Platinum Resistant Recurrent Ovarian Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a Prospective, Single-arm, Phase 2 clinical trial. The purpose of this study is to find out if taking Utidelone Capsules together with Fruquintinib Capsules is safe and works well for people with platinum-resistant ovarian cancer . Researchers will look at the Objective Response Rate, Progression-Free Survival, Overall Survival, safety, and any side effects.

Conditions

• Platinum Resistant Ovarian Cancer

Interventions

Type	Name	Description
DRUG	Utidelone Capsules	60 mg/m2 orally, days 1 to 5, per cycle
DRUG	Fruquintinib Capsules	5 mg orally, days 1 to 14, per cycle

Timeline

• Start date: 2025-07-01
• Primary completion: 2027-06-30
• Completion: 2028-06-30
• First posted: 2025-05-15
• Last updated: 2025-05-15

Locations

1 site across 1 country: China